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Background: Evidence of serotonergic involvement in vestibular pathway contributions 
to migraine and balance disorders is compelling. Serotonergic 5-HT1B and 5-HT1D recep-
tors are expressed extensively in inner ear ganglia of monkeys and rats. The serotonergic 
5-HT1F receptor is also a target of triptans. This study describes its distribution in vestib-
ular and trigeminal ganglia of monkeys.
Methods: Using primary polyclonal antibodies raised against oligopeptides specific 
for the human 5-HT1F receptor, neuronal somatic area and intensity of immunoreactive 
vestibular and trigeminal ganglia were quantified.
results and Discussion: Virtually all vestibular and considerable trigeminal ganglia 
showed positive 5-HT1F receptor immunoreactivity. Inferior and superior vestibular ganglia 
staining appeared confined to distinct cell regions, varying considerably among cells of 
different sizes: more intense in small, punctate in some medium and regionally polarized 
in some large cells. Analyses of average somatic vestibular neuronal immunoreactive 
intensity identified mainly medium sized cells with high standard deviation of intensity 
corresponding to punctately stained cells. Less variability occurred in somatic intensity 
staining and cellular distribution among 5-HT1F receptor immunopositive trigeminal 
ganglia. Most exhibited similar punctate staining patterns, higher mean somatic immu-
noreactive intensity and larger neuronal somatic size proportions per size distribution 
subpopulation compared to vestibular ganglia size distribution populations. Centrally 
directed vestibular ganglion neuronal processes, cochlear inner hair cells, vestibular hair 
cells and blood vessels in vestibular maculae and cristae were immunoreactive. The 
5-HT1F receptor expression in vestibular ganglia shows complex variable staining intensity 
patterns associated with cell size of immunopositive neurons, not seen in immunopositive 
trigeminal ganglia and not previously evident with 5-HT1B and 5-HT1D receptor subtype 
immunoreactivity in vestibular ganglia. These data motivate exploration of 5-HT1 receptor 
oligomerization and ligand functional selectivity in differential serotonergic involvement in 
co-morbidity of migraine and balance disorders. Similar findings in cochlear inner hair 
cell afferents are applicable to migraine-related tinnitus or hypercusis (phonophobia).
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inTrODUcTiOn
The co-morbidity of migraine and balance disorders with psychi-
atric disorders has been well documented (1–6). One hypothesis 
proposed regarding these comorbidities phenomenon cites an 
apparent convergence of afferent channels of vestibular and 
trigeminal ganglia in shared central pathways for vestibular and 
nociceptive signal transduction (7). Numerous reports (8–12) 
support the concept that otologic features of vertigo associated 
with migraine are attributable to parallel activation of vestibular 
and cranial nociceptive pathways (7).
In the light of the convincing evidence of vestibular symp-
toms with an undeniable migrainous etiology, the International 
Headache Society (IHS) in conjunction with the Barany Society 
forwarded diagnostic criteria for the condition now known 
as vestibular migraine (13). Vestibular migraine is currently 
recognized as an episodic syndrome that may be associated with 
migraine by the IHS (14), a clinical condition manifesting in a 
considerable number of migraineurs who present with vestibular 
symptoms (15). Based on the considerable and rapidly expand-
ing accumulation of reports on genetic, in vitro cell biological, 
animal model as well as human clinical studies on mechanisms 
triggering migraine (16–22) vestibular migraine may be viewed 
as a variant created by the convergence of vestibular information 
in migraine circuits (15).
A number of more recent reports also support the proposi-
tion that serotonergic mechanisms play a pivotal role in both 
peripheral and central vestibular pathway contributions to 
migraine and balance disorders (23, 24). Not surprisingly, 
serotonergic mechanisms are also suggested to be involved 
in mechanisms of vestibular migraine (15). Vestibular and 
cranial nociceptive pathways do possess striking similarities in 
neurochemical milieu and express serotonin receptor subtypes 
that are known to be targets for anti-migraine drugs, such as 
the triptans. Furthermore, triptans feature prominently as 
one of the current treatments options for migraine-associated 
balance disorders as well as for overt vestibular migraine (23, 
25–27). Although triptans, such as rizatriptan, are particularly 
strong agonists at serotonergic 5-HT1B and 5-HT1D receptors, 
they also have affinity for 5-HT1A (28, 29) and 5-HT1F (29, 30) 
receptors.
The serotonergic 5-HT1B and 5-HT1D receptors are expressed 
prominently in the inner ear of rats and monkeys (31). 
Immunoreactivity for these receptors was mainly associated with 
vestibular ganglion cells, spiral ganglion cells, the vestibulococh-
lear nerve fibers, the spiral ligament, and stria vascularis (31). 
Another serotonin receptor subtype that has recently generated 
interest in its possible application as a promising pharmacological 
target option in the treatment of migraine is the 5-HT1F receptor. 
Selective 5-HT1F receptor agonists would produce fewer vascular 
side effects and potentially provide an alternative for patients 
with a history of increased risk of coronary artery disease in 
whom the use of the less selective vasoactive triptans would 
be contra-indicated (27, 32). In this present study, we examine 
immunoreactivity for the 5-HT1F receptor in macaque vestibular 
and trigeminal ganglia. Our findings support our proposal that 
the 5-HT1F receptor may also act in concert with the previously 
identified subtypes in the vestibular ganglia as mediators of sero-
tonergic transmission on peripheral vestibular function.
MaTerials anD MeThODs
ethics
The study used archival tissues from primates that were euthanized 
at the conclusion of physiological studies. Two of the macaques 
(one male and one female adult) were used in neurophysiological 
recording and tract tracing experiments; the other three adult 
macaques (two females and one male) were acute control animals 
from studies of lymphoid chemokine responses to inoculation 
with simian immunodeficiency virus (33). Body weights ranged 
from 5 to 7.2 kg. The earlier studies were completed under pro-
tocols (#0898008, 0004002, 01084828, and 0304558) approved 
by the University of Pittsburgh Institutional Animal Care and 
Use Committee (IACUC) and fully certified to comply with 
the National Institutes for Health (NIH) and the United States 
Department of Agriculture standards and regulations for humane 
animal utilization. The University of Pittsburgh maintains an 
OLAW approved PHS Animal Welfare Assurance and a USDA 
registration. All experiments were designed to minimize the 
number of animals used and their suffering. These tissues were 
obtained from euthanized animals at the conclusion of other 
studies.
The animals were housed in the AALAC-accredited animal 
facility at the University of Pittsburgh during the studies without 
food restriction. The room temperature is maintained at 70 ± 4 
Fahrenheit. The facility uses standard stainless steel primate cag-
ing (29″ × 30″ × 33″ or 29″ × 30″ × 69″). Macaques are typically 
housed in pairs. Individualized enrichment is provided at the 
facility by specialized, professional staff; with components that 
include perches in the cage; forage mix, forage boards, puzzle 
feeders, fruits/vegetables, assorted treats, mirrors, and stainless 
steel hanging toys/devices that are provided within the cage. 
Husbandry: pans scraped or hosed daily and cages sanitized at 
least once every 2 weeks.
Non-human primates are fed a commercially available bis-
cuit type diet twice daily. The quantity of biscuits offered may 
be adjusted up or down based on individual body condition 
scores. Dietary supplements of fruit, vegetables, forage mixes, 




Temporal bone sections were used from a total of five adult 
macaque monkeys of both sexes. Three adults were acute control 
rhesus macaques from simian immunodeficiency virus studies 
(33) and two adult macaques had been subjects in chronic 
neurophysiology and tract tracing experiments (34, 35)]. The 
monkeys were previously euthanized between 1999 and 2002 
with pentobarbital sodium and perfused transcardially with 
phosphate buffered saline (pH 7.2–7.4), followed by either per-
fusion fixation with 4% paraformaldehyde in phosphate buffered 
saline or paraformaldehyde-lysine-sodium metaperiodate (PLP) 
FigUre 1 | Western blot analysis. Rat and monkey medulla oblongata  
P1 and P2 fractions were prepared from homogenized fresh tissue by 
centrifugation. Aliquots were placed in separate lanes (labeled) for protein 
separation on a NuPAGE™ 10% Bis-Tris gel and were electro-blotted onto an 
Invitrolon™ PVDF membrane (Invitrogen). Molecular weight standards were 
placed in the far left lane for calibration. Binding of each primary antibody 
(1:1000 dilution) was detected with an alkaline phosphatase-conjugated 
secondary antibody and histochemical substrate (WesternBreeze™, 
Invitrogen). The blot was digitized with a flatbed photo scanner (Epson V500).
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fixative. Necropsies were performed immediately after comple-
tion of the perfusion (dates: 23 September 1999, 28 September 
1999, 17 November 1999, 20 May 2002, and 26 September 
2002). The trigeminal ganglia were removed from the skull and 
processed separately for paraffin embedding. Decalcification 
of the temporal bone was achieved by treatment with 10% 
formic acid followed by an overnight soak in 5% sodium sul-
fate following standard methods (36). The tissue was further 
processed through graded ethanol concentrations and xylene, 
embedded in paraffin, trimmed, sectioned at 7–8 microns in 
the mid-modiolar plane and archived until required. There are 
no reports in the literature concerning potential effects of brief 
pentobarbital exposure on the distribution of immunoreactive 
serotonin receptor protein subunits.
Immunohistochemical Procedures
For the immunohistochemical procedures, the tissue sections 
were first de-paraffinized, rehydrated through descending 
ethanol concentrations to deionized water, exposed to formalin 
vapor, then treated for 10 min with 0.9% hydrogen peroxide in 
deionized water followed by thorough rinsing with deionized 
water. Subsequently, antigen retrieval was performed by heat-
ing the sections in a low pH (6.0) sodium citrate citric acid 
buffer solution for 20 min at 80–85°C followed by a thorough 
rinse in PBS. The sections were then treated with a blocking 
solution of 10% triton X-100, 2% bovine serum albumin and 
either normal horse or normal goat serum in PBS for 1 h at 
room temperature. This was followed by 24  h incubation in 
a polyclonal antibody raised against oligopeptides specific 
for the human 5-HT1F N-terminus (Imgenex, 7182) or 
C-terminus (Imgenex, 71821). These 5-HT1F antibodies had 
been affinity-adsorbed against their respective immunogens, 
synthetic oligopeptides from the N- and C-termini of the 
human receptor protein. Western blots of P1 and P2 fractions 
from rat and monkey brain tissue (Figure 1) showed a bands 
at between 40 and 50 kDa with the C-terminus as well as what 
may appear to be doublet bands at about 90 kDa particularly 
with the N-terminus antibody. The multiple bands with the 
affinity-adsorbed C-terminus antibody likely reflect the known 
homo- and hetero-oligimerization properties of the 5-HT1 
receptor family (37–44). The primary antibodies were diluted 
in blocking solution (1:1000–5000). In parallel negative con-
trol experiments, the primary antibody was omitted. Following 
incubation in primary antibody, the sections were thoroughly 
rinsed with PBS and then further incubated in biotinylated 
secondary antibody (Jackson Laboratories, West Grove, 
PA, USA) diluted 1: 500 in 2% BSA in PBS for 1  h at room 
temperature. After three vigorous rinses to remove secondary 
antibody, the sections were incubated for 1 h in Vectastain ABC 
reagent (Vector Laboratories) and thoroughly rinsed in PBS 
again. Subsequently, the sections were treated with a solution 
of Trizma pre-set crystals (Sigma; 1.58  mg/200  ml) followed 
by staining with 3,3′-diaminobenzidine tetrahydrochloride 
(DAB stain) in sodium acetate buffer (pH 6.0). The final steps 
involved dehydrating the sections by successive treatment with 
increasing concentrations of alcohol, followed by treatment 
with xylene and cover-slipping with DPX.
Quantification Methods
Digital images of temporal bone tissue sections, stained immuno-
histochemically for 5-HT1F receptors, were obtained with a Nikon 
Eclipse E600N microscope outfitted with a Spot RT Monochrome 
camera (Model 2.1.1, Diagnostic instruments, inc., Sterling 
Heights, MI, USA). The MetaMorph software (ver. 6.1r4 Universal 
Imaging Corporation, Downingston, PA, USA) was used to 
conduct the quantification of photographed images captured on 
a Pentium-based computer. A series of 12 bit digital images were 
taken with a 20× objective and the neuronal somatic area as well 
as intensity of 5-HT1F receptor immunoreactivity of vestibular 
ganglia was quantified. A total of 9,991 ganglion cells were sam-
pled from temporal bones from five monkeys. Three temporal 
bone sections were collected per slide and sections were sampled 
350 microns apart to ensure cells were not double counted. A total 
of 40 slides (8 per animal) were analyzed. MetaMorph was used to 
manually outline and automatically log the statistics of neuronal 
cell bodies complete with nuclei and nucleoli. The absolute zero 
calibration for differences in optical transmission between the 
light source and CCD element were obtained by measuring areas 
of the images that were purely glass slide, cover slip, and mount-
ing medium and, therefore, devoid of tissue. Readings between 
different slides were initially normalized by subtracting the 
absolute zero calibration value from recorded data. The ganglion 
and peripheral nerve parenchyma captured in each image had 
the same baseline optical density as non-immunoreactive somata 
and, therefore, served as control regions from which background 
staining intensity was obtained. Final normalization of data was 
achieved by subtracting the background values.
FigUre 2 | Photomicrograph of 5-hT1F receptor immunoreactive vestibular ganglion cells in the macaque. (a) Inferior and (B) superior vestibular 
ganglion. Note the greater intensity of the immunoreaction in small ganglion cells and the association of immunoreactive fibers with blood vessels. The calibration 
bars represent 40 microns. Staining patterns and associated cell sizes in representative vestibular ganglion cells; (c,F) large to intermediate sized cells showing 
punctuate staining associated with the cell membrane. (D,g) Large to intermediate sized cells with demarcated immunoreactive regions at one pole of the cell. 
(e,h–K) A few intermediate and mainly small sized cells with intense, reasonably homogenous somatic immunoreactivity.
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Statistical Analysis
The normalized data were subjected to standard statistical 
analyses employing SYSTAT 11 (SYSTAT Software, Inc.). The 
conformity of the data to assumptions of underlying normality 
and having identical distribution were assessed using quantile and 
normal probability plots. Specific hypotheses under assumptions 
of normality were assessed using analysis of variance (ANOVA) 
with least significant differences (LSD) tests. Furthermore, the 
distribution of any given data set as a mixture to three normal 
Gaussian populations was estimated by k-means cluster analysis 
followed by order statistics approach, achieved adhering to previ-
ously described procedure (35).
resUlTs
expression of the 5-hT1F receptor 
subtype in Vestibular Periphery
Virtually, all vestibular ganglion cells, as well as some vascular 
endothelial cells, were immunoreactive for the serotonergic 
5-HT1F receptor (Figures  2A,B) in the monkey temporal bone 
sections. The results were the same for the antibodies recognizing 
the N-terminus and C-terminus. The intensity and intracellular 
distribution of 5-HT1F receptor immunoreactivity varied consid-
erably among vestibular ganglion cells of different sizes. Cluster 
analysis indicated that the size distribution of the ganglion cells 
expressed as mean circular diameter (square root soma area/
pi × 2) in microns is consistent with three normally distributed 
(Gaussian) populations consisting of 24.3% from a of 30.8 ± 6.4 
(SD) micron population, while 41.2 and 26.5% belonged to popu-
lations of average circular diameters of 47.4 ± 4.6 (SD) microns 
and 61.2 ± 7.0 (SD) microns, respectively. Smaller sized ganglion 
cells tended to be stained more intensely than larger ganglion 
cells in both the inferior and the superior vestibular ganglia 
(Figures  2A,B, compare Figures  2C,D with Figures  2H,K). 
These included small (and a few intermediate) sized cells with 
intense, reasonably homogeneous somatic immunoreactivity 
(Figures  2H,I–K,E) as well as intermediate to large sized cells 
showing punctuate staining associated with the cell membrane 
(Figures 2C,F). In addition, some large to intermediate sized cells 
had strongly demarcated immunoreactive regions at one pole of 
the cell (Figures 2D,G).
Quantitative analysis of the somatic immunoreactivity inten-
sity of 5-HT1F positive neurons is illustrated in Figure 3. Normal 
probability plots of the intensity data (square root of IR intensity) 
for the three size intensity populations (small, medium, and large) 
showed that vestibular ganglion cells with higher immunoreac-
tive intensity tended to be larger than lower staining intensity 
cells (Figure 3A). Cluster analysis of mean cell staining intensity 
(square root of mean IR intensity) identified two somatic stain-
ing intensity populations comprising 49.1% of cells with a low 
mean somatic intensity (17.2 ± 2.7 arbitrary units) and 50.9% of 
cells with a higher mean somatic intensity (23.9 ± 2.9 arbitrary 
units). Several interesting characteristics relating to somatic 
immunoreactive intensity and cell size distribution were further 
revealed. For example, within the subpopulation of ganglion cells 
with low mean somatic staining intensity, small size cells exhibited 
significantly less intense staining (LSD tests, p < 0.01) compared 
to medium and large size cells that did not differ from each other 
(LSD tests, not significant). Interestingly, among the subpopula-
tion of ganglion cells with high mean somatic staining intensity, 
medium size cells differed significantly in intensity from small and 
large size cells (LSD tests, p < 0.01), both of which did not show 
significant difference (LSD test, not significant) from each other.
These different features are also illustrated in the scatter plots 
of relationship between the mean somatic IR and SD of somatic 
IR for individual cells (Figures 3B,C). These plots show subpopu-
lations with the distinct neuronal staining patterns identified in 
Figure  2; lines have been inserted in Figures  3B,C to indicate 
boundaries that are (1) 1.3 SD units from means of both small and 
medium sized populations (left line) and (2) 1.5 SD units from 
the means of both medium and large cell populations (right line). 
The low IR intensity cell population (Figure 3B) consists largely 
of cells with low SD, suggesting homogeneous distribution of IR 
FigUre 3 | statistical analysis of neuronal 5-hT1F receptor immunohistochemistry in vestibular ganglion cells from monkey temporal bones. (a) 
Normal probability plots show ganglion cells with higher immunoreactive intensity tend to be larger than lower staining intensity cells. Scatter plots show (B) low and 
(c) high intensity staining subpopulations of the distinct neuronal staining patterns identified in Figure 2; the red square shows a subpopulation of mainly medium 
size cells depicted in Figure 2F.
FigUre 4 | Photomicrograph of 5-hT1F receptor immunoreactive neurons in the macaque trigeminal ganglia. (a) Notice the presence of considerably 
fewer immunopositive cells in general and fewer immunopositive large size cells in particular, compared to the vestibular ganglia. The calibration bar represents 40 
microns; (B–l) Staining patterns and associated cell sizes in representative trigeminal ganglion cells. Most 5-HT1F receptor immunopositive trigeminal ganglia have a 
similar punctate staining pattern. A few large (B,D) and small (l) cells showed more intensely stained background cytoplasm.
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within the soma. The subpopulation of large sized cells in this low 
IR intensity group correspond to cells illustrated in Figures 2C,D, 
while the medium and small sized cells are represented in 
Figures 2G,K. On the other hand, a subpopulation of intensely 
immunoreactive, punctately stained medium and a few small 
sized cells (demarcated red square in Figure 3C) has cells with 
highly variability (inhomogeneous) intra somatic immunoreac-
tivity, thus corresponding to cells represented in Figures 2F,H. 
Within the population of high IR intensity cells, there were some 
small sized cells with more homogeneous intense staining. These 
have a low variability in intrasomatic IR intensity (low SD) and 
are exemplified in Figure 2I.
expression of the 5-hT1F receptor 
subtype in Trigeminal ganglia
The intensity of somatic 5-HT1F receptor immunoreactivity was 
also analyzed qualitatively and quantitatively in monkey trigemi-
nal ganglia. By contrast, the prevalence of immunoreactivity for 
the 5-HT1F receptor was considerably lower in trigeminal gan-
glion cells with only 74.2% of neurons showing immunopositivity 
above background. However, the full range of size categories from 
small through medium to large cells were represented among 
positively stained neurons (Figure  4). Unlike 5-HT1F receptor 
immunopositive vestibular ganglion cells, there was considerably 
FigUre 5 | statistical analysis of neuronal 5-hT1F receptor immunohistochemistry in trigeminal ganglion cells from monkey temporal bones. (a) Bar 
graph comparing the identified small, medium, and large sized cell subpopulations shows larger neuronal somatic dimensions for trigeminal ganglion cells compared 
to vestibular ganglion cell subpopulations; (B) Normal probability plots show ganglion cells with higher immunoreactive intensity tend to be larger than lower staining 
intensity cells, low (c) and high (D) somatic staining intensity populations identified by cluster analysis of log mean cell staining intensity data show a larger 
proportion of TG cells fell in the low intensity subpopulation.
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less variability in intensity and cellular distribution among vari-
ous trigeminal ganglion cells (Figure 4). The majority of 5-HT1F 
receptor immunopositive trigeminal ganglion cells exhibited a 
similar punctate staining pattern (Figures  4B–L). In addition, 
a few large (Figures  4B,D) and small (Figure  4L) trigeminal 
ganglion cells showed more intense staining in background 
cytoplasm.
Cluster analysis revealed that size distribution of 5-HT1F 
receptor immunopositive trigeminal ganglion cells similar to 
immunopositive vestibular ganglion cells is consistent with 
three normally distributed (Gaussian) populations comprising 
38.0% from a 49.5 ± 10.0 (SD) micron average circular diameter 
population, 42.2% from a population with a mean circular diam-
eter of 79.3 ± 9.3 (SD) micron and 19.8% from a 114.0 ± 13.7 
(SD) micron average circular diameter. It is noteworthy that the 
small, medium, and large sized cell subpopulations identified for 
trigeminal ganglion cells showed consistently larger neuronal 
somatic dimensions compared to their vestibular ganglion cell 
subpopulation counterparts (Figure 5A).
Quantitative analysis of the somatic immunoreactivity 
intensity of 5-HT1F receptor positive trigeminal ganglia further 
revealed similarities and additional differences compared to ves-
tibular ganglia. The normal probability plots (Figure 5B) showed 
that, similar to vestibular ganglion cells, trigeminal ganglion cells 
with higher immunoreactive intensity tended to be larger than 
lower staining intensity cells. The scatter plots of the intracellular 
mean IR versus intracellular SD of low (Figure  5C) and high 
(Figure 5D) somatic staining intensity populations (identified by 
FigUre 6 | Photomicrograph of 5-hT1F receptor immunoreactive spiral ganglion cell dendrites in the macaque organ of corti. (a) The axons could be 
traced from the spiral ganglion to the base of the inner hair cells. No 5-HT1F receptor immunoreactive axons were associated with the outer hair cells. The calibration 
bar represents 100 microns. (B,c) Examples of staining in association with the inner hair cells are shown below at higher magnification (bar = 20 microns).
FigUre 7 | Photomicrograph of 5-hT1F receptor immunoreactivity associated with both the neurepithelium and blood vessels. (a) Macaque posterior 
semicircular canal crista (left) and (B) saccular macula. The calibration bar represents 60 microns.
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cluster analysis of mean cell staining intensity data for trigeminal 
ganglion cells) showed general similarity in cell size distribution 
patterns. Although the linear relationship between soma size of 
the high intensity population and the SD of the somatic IR is 
statistically significant (p < 0.01), it only accounted for 2.3% of 
the variance. Both subpopulations, however, showed consistently 
higher values compared to their vestibular ganglion counter-
parts. Specifically, 49.0% showed a low mean somatic intensity 
(16.4 ± 4.0, square root arbitrary units), while 51.0% had a higher 
mean intensity (26.5 ± 3.7, square root arbitrary units).
expression of the 5-hT1F receptor 
subtype in the auditory Periphery
Intense 5-HT1F receptor staining is associated with the peripheral 
afferents of the eighth nerve. In the cochlea, immunopositive 
axons could be traced distally from spiral ganglion cells to 
the organ of Corti (Figure  6A). These axons ended in either 
large, knob-like terminals (Figure  6B) or calyx-like endings 
(Figures 6A,C) on inner hair cells. No positive axons were seen 
traversing the tunnel of Corti or at the outer hair cells. In the 
cristae ampullares (Figure 7A) and maculae (Figure 7B), immu-
noreactivity was associated with blood vessels and cell bodies of 
hair cells, where it could appear diffusely or as bouton-like or 
calyx-like terminations.
DiscUssiOn
In addition to migraine, the complex interplay between the vari-
ous serotonin receptors in the CNS has been linked to responses 
to stress, complex cognitive responses, anxiety, and spatial 
memory. The strong parallels in serotonergic receptor expression 
between migraine pathways and vestibular pathways (6, 7, 24, 45) 
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further support the notion that 5-HT1 receptor subtypes may play 
a role in modulating signs and symptoms of vestibular migraine. 
In particular, the higher prevalence of expression of 5-HT1F (and 
1B/D receptors) in the vestibular ganglion cells suggests a crucial 
role for these receptor subtypes.
Previous studies from our laboratory demonstrated that sero-
tonergic 5-HT1B and 5-HT1D receptors are expressed extensively 
in inner ear ganglion cells of all sizes in monkeys and rats (31). In 
this study, we describe the distribution in monkey vestibular gan-
glion cells of the 5-HT1F receptor subunit, another serotonergic 
receptor subtype that has high affinity for triptans (46, 47). Our 
results show that 5-HT1F receptor expression in macaque ves-
tibular ganglion cells not only shows obviously different cellular 
distribution patterns than 5-HT1B and 5-HT1D subtypes, but also 
differs relative to 5-HT1F receptor subtype in trigeminal ganglion 
cells. While 5-HT1B and 5-HT1D receptor immunoreactivity have 
been detected in 97 and 87% of macaque vestibular ganglion cells, 
respectively (31), 5-HT1F receptor immunoreactivity was present 
above background in virtually all (99.99%) vestibular ganglion 
neurons. The appearance of heavy immunoreactivity in associa-
tion with vestibular hair cells was consistent with contributions 
from calyceal, bouton, and dimorphic terminals described by 
others (48–50). Hence, a high level of co-localization between 
5-HT1B, 5-HT1D, and 5-HT1F receptor subunits in vestibular 
ganglia (on the order of 90%) must be considered as a factor in 
the efficacy of triptans (and SSRIs) in vestibular migraine (49).
Two main varieties of 5-HT1B/D/F receptor immunohistochemi-
cal staining intensity patterns have been identified in trigeminal 
and dorsal root ganglion cells, which are often associated with cell 
size. These include staining described as either “dense” granular 
or less dense “punctate” staining within the cytoplasm and associ-
ated mainly with large sized cells (51, 52). Vestibular ganglion 
cells show a clear association between cell size and somatic 
immunoreactivity intensity of 5-HT1F receptor immunopositive 
ganglion cells, which was not seen previously with 5-HT1B and 
5-HT1D subunit staining (31). While more intense 5-HT1F recep-
tor somatic immunoreactivity was clearly associated with smaller 
sized ganglion cells, a population of mainly medium size and a 
few small size cells with punctate, dense staining previously could 
be identified quantitatively by a high somatic mean intensity as 
well as high SD of intensity across the soma. The heterogeneity in 
staining patterns suggests that different phenotypes of vestibular 
ganglion cells may be characterized on the basis of both soma size 
and intracellular serotonin 1 receptor distribution. For example, 
one expects that both thick calyx afferents, which arise from 
large, calretinin positive vestibular ganglion cells that show little 
or no overlap in staining with peripherin, another biochemical 
marker known to stain bouton-only vestibular afferents (53–59) 
and afferents arising from “medium” calbindin positive vestibular 
ganglion cells that show some overlap (48, 57) would have varied 
distribution in 5-HT1F receptor expression.
The heterogeneity in intracellular 5-HT1 receptor staining 
patterns may be noteworthy in light of both structural differences 
in native 5-HT1 receptor subtypes and evidence for homo- and 
hetero-oligomerization. Serotonergic 5-HT1 receptors are among 
the G-protein-coupled receptors (GPCRs) that are known to acti-
vate canonical as well as non-canonical second messenger signal 
pathways. Functional selectivity or biased signaling occurs when 
“biased” ligands preferentially or differentially activate one sign-
aling pathway over another, with distinct potencies and efficacies; 
as opposed to unbiased agonists that activate alternative pathways 
equally (60). Although recent studies have provided evidence of 
critical structural determinants for 5-HT1B receptor–ligand rec-
ognition and subtype selectivity (61), there are no known similar 
reports on either the 5-HT1D or 5-HT11F receptor subtypes. While 
the 5-HT1B and 5-HT1D receptors are closely related on the basis 
of degree of homology in the sequence alignment (62), they are 
divergent from the 5-HT1F receptor subtype (63). In addition, 
there is ample evidence that 5-HT1B and 5-HT1D receptors have 
the propensity to form homodimers when expressed alone and 
heterodimers when co-expressed in vitro (42, 43). The concept 
of 5-HT1B and 5-HT1D homodimers and heterodimers opens 
interesting directions for exploring interactions between co-
expressed 5-HT1B, 5-HT1D and 5-HT1F receptors. Studies suggest 
that heterodimerization between 5-HT1B and 5-HT1D receptors 
may require a co-translational or specific cellular mechanism 
and appears to be favored over homodimerization when these 
subtypes are co-expressed (43). Although there is a dearth of 
information on oligomerization of 5-HT1F receptors, recent 
evidence indicates that phosphorylation by PKA is involved in 
regulating the stability of heteromers of dopamine and adenosine 
G-protein-coupled receptors through interactions at short linear 
motifs on the receptor subunit proteins (64). Hence, dynamic 
regulation of heteromerization and oligomerization may be a 
factor in understanding both fluctuations within and individual 
and inter individual differences in effects of ligands.
Initial studies of 5-HT1B and 5-HT1F receptor heterodimers 
showed serotonin binding kinetics intermediate to 5-HT1B and 
5-HT1D receptor homodimers, which suggests a similar phar-
macology (42, 43). However, data from studies on other related 
GPRCs, such as GABAB (37–41) and opioid receptors (44), 
suggest that heterodimerization of GPRCs may result in novel 
functionality. It is, therefore, a possibility that heterodimerization 
between 5-HT1B and 5-HT1D receptors may result in greater diver-
sity of 5-HT1 receptor function in general and 5-HT1F receptor 
activity in particular, on account of inter-receptor interactions 
that maybe potentially modulated by other receptor subtypes. 
Therefore, experiments targeted at elucidating the possible alter-
ing effects of receptor hetero-oligomerization between 5-HT1B, 
5-HT1D, 5-HT1F, and indeed other receptor types on functional 
selectivity in signal transduction would be crucial to understand-
ing receptor–ligand interactions and designing subtype-selective 
and more effective serotonergic drugs.
The quantitative distribution of 5-HT1B, 5-HT1D, and 5-HT1F 
receptor subtypes has been examined previously in rat trigeminal 
and/or dorsal root ganglion cells (51, 65–68), with co-localized 
staining primarily in the cytoplasm of immunopositive ganglion 
cells. More recent studies further demonstrated no apparent 
differential in both distribution and staining intensity pattern 
between the 5-HT1 receptor subtypes in rat trigeminal and dorsal 
root ganglia (52), leading the authors to conclude that a simple 
correlation between the level of expression of these receptors in 
nociceptive ganglia (trigeminal and dorsal root ganglia) is not 
sufficient to explain the efficacy of triptans in migraine and cluster 
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headaches. In the case of macaque trigeminal ganglion cells in 
our study, expression of 5-HT1F receptor immunoreactivity was 
primarily in small and medium sized neurons with a more limited 
number of large sized ganglion cells showing immunopositivity.
These findings corroborate previous observations made for 
cell size distribution for 5-HT1F immunopositive cells in rat 
trigeminal ganglia (16, 69, 70). Interestingly, Ma (2001) reported 
that 5-HT1F receptor expression in rat trigeminal ganglia was 
largely in small diameter cells, while our results in monkeys 
showed small portion of 5-HT1F receptor immunopositive large 
diameter cells in addition to small and medium sized cells. 
Inter-species variations in receptor expression patterns are far 
from unprecedented, as was evident in our previous studies 
showing differential association between intensity of expression 
of 5-HT1B and 1D receptors in rat and monkey ganglion cells (Ahn 
and Balaban, 2011). It is, therefore, not surprising that quantita-
tive expression of immunopositive cell size populations seem 
to vary slightly between rat and monkeys. However, our other 
related discoveries highlight several distinctions in quantitative 
and qualitative expression of 5-HT1F receptor immunoreactivity 
between macaque vestibular and trigeminal ganglion cells. First, a 
lower proportion (74.2%) of trigeminal ganglion cells was 5-HT1F 
receptor immunoreactive. Second, there was considerably less 
variability in somatic intensity staining and cellular distribution 
among 5-HT1F receptor immunopositive trigeminal ganglion 
cells with the majority exhibiting similar punctate staining 
patterns. Finally, trigeminal ganglion cells showed higher mean 
somatic immunoreactive intensity and neuronal size proportions 
for the three size distribution subpopulation identified (small, 
medium, and large sized cells) were larger compared to vestibular 
ganglion cell size distribution subpopulations. For instance, the 
small and medium sized trigeminal ganglion cell subpopulations 
showed similar somatic size proportions with medium and large 
vestibular ganglion cells subpopulations, respectively.
Agonists at 5-HT1F receptors have been purported to relieve 
migraine possibly via a number of mechanisms unrelated to 
vasoconstriction. These mechanisms include blockade of neuro-
genic plasma protein extravasation (46, 71, 72), inhibition of c-fos 
expression (73, 74) and inhibition of neuronal firing (75) in the 
trigeminal nucleus caudalis. Furthermore, inhibition of plasma 
protein extravasation by serotonin agonists has been correlated 
specifically with activity at 5-HT1F (46) and not 5-HT1B or 5-HT1D 
receptor subtypes (76, 77) further corroborating possible alternate 
but complimentary mechanisms of action for these triptan sensi-
tive receptor subtypes. Indeed, these alternative complimentary 
mechanisms are likely in operation in the vestibular periphery. 
Koo and Balaban (78) demonstrated that intravenous serotonin 
infusions can elicit plasma extravasation in specific inner ear tis-
sues. The widespread distribution of serotonin-induced plasma 
extravasation in the apical spiral ganglion, modiolus as well as 
intralabyrinthine superior and inferior vestibular nerve provided 
a “proof-of-concept” that concurrent inner ear and meningeal 
extravasation could to vestibular symptoms like vertigo and 
sound sensitivity associated with migraine.
Interestingly, differences in distribution of 5-HT1F versus 
5-HT1D in the vestibular periphery are also corroborated by 
our results. While there is evidence of differential expression of 
5-HT1D and 1F receptors in planum semilunatum cells as well as 
vasculature in the crista ampullaris (24), our studies showed that 
immunoreactivity for 5-HT1F receptors was closely associated 
with a vestibular and spiral ganglion cells. Our findings further 
corroborate the notion that variations in 5-HT1F and 1D receptor 
subtype expression in vestibular organs may contribute to medi-
ating multiple influences of triptans on these organs. In addition, 
similar to what has been speculated for the vestibular ganglion, 
the phenomena of possible receptor oligomerization between 
5-HT1 receptors subtypes in the vestibular periphery may also 
further contribute to determining the downstream signaling 
pathway cascades ultimately triggered.
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